Arterial hypertension and atrial fibrillation: a dangerous “friendship” that cannot be ignored!

V.A. Skybchyk, S.D. Bablyak, Yu.O. Matviyenko


In the article, the authors briefly discuss the effect of arterial hypertension on the onset and progression of atrial fibrillation. The importance of uncontrolled hypertension as a serious risk factor for stroke in patients with atrial fibrillation is emphasized. The main aspects of using special diagnostic and prognostic scales useful in the treatment of patients with combined pathology (arterial hypertension and atrial fibrillation) are analyzed. Focus is made on the need of using these scales in real clinical practice in order to reduce both the risk of ischemic strokes and systemic venous thromboembolism, as well as serious bleedings.


arterial hypertension; atrial fibrillation; bleeding risk and anticoagulant selection scales


Lip G.Y.H., Coca А., Kahan Т. et al. Hypertension and Cardiac Arrhythmias: Executive Summary of a Consensus Document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). European Heard Jornal — Cardiovascular Pharmacotherapy. 2017. Vol. 3. P. 235-250.

Kakkar A.K., Mueller I., Bassand J.P. et al. Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry. Public Library of Science. 2013, May. Vol. 8(5). e63479.

Connolly S.J., Eikelboom J., Joyner С. et al. Apixaban in Patients with Atrial Fibrillation. The New England Journal of Medicine. 2011. Vol. 364. P. 806-817.

Potpara T.S., Stankovic G.R., Beleslin B.D. et al. A 12-Year Follow-up Study of Patients With Newly Diagnosed Lone Atrial Fibrillation: Implications of Arrhythmia Progression on Prognosis: The Belgrade Atrial Fibrillation Study. Chest. 2012. Vol. 141. P. 339-347.

Lip G.Y., Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010. Vol. 137. P. 263-272.

Kahan T., Bergfeldt L. Left ventricular hypertrophy in hypertension: its arrhythmogenic potential. Heart. 2005. Vol. 91(2). P. 250-256.

Potpara T.S., Polovina M.M., Marinkovic J.M. et al.

A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. Int. J. Cardiol. 2013. Vol. 168. P. 4744-4749.

Lauer A., Pfeilschifter W., Schaffer C.B. et al. Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies. Lancet Neurol. 2013. Vol. 12. P. 394-405.

Giugliano R.P., Ruff C.T., Braunwald Е. et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. The New England Journal of Medicine. 2013. Vol. 369. P. 2093-2104.

Olesen J.B., Lip G.Y., Lindhardsen J. et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a “real world” nationwide cohort study. Thromb Haemost. 2011. Vol. 106. P. 739-749.

Chao T.F., Liu C.J., Wang K.L. et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J. Am. Coll. Cardiol. 2015. Vol. 65. P. 635-642.

Скибчик В.А., Соломенчук Т.М. Практичні аспекти сучасної кардіології. 2-ге вид., доповнене. Львів: Медицина світу, 2019. 424 с., іл.

Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 2016. Vol. 37(38). P. 2893-2962.

Pisters R., Lane D. A., Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010. Vol. 138. P. 1093-1100.

Apostolakis S., Sullivan R.M., Olshansky B. et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest. 2013. Vol. 144(5). P. 1555-1563.

Copyright (c) 2019 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2020


   Seo анализ сайта